Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...

Pinnacle Associates Ltd. reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 44.4% in the ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today. Joseph Stringer has given his ...

Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.27%.

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.00% to $475.08 Wednesday, on what proved to be an all-around rough trading ...

Vertex Pharmaceuticals is a global biotechnology ... Analysts typically rate each stock once per quarter. Some analysts publish their predictions for metrics such as growth estimates, earnings ...

Vertex Pharmaceuticals (NASDAQ:VRTX ... an increase of $100 million from previous projections. The company's stock has shown resilience, with a year-to-date performance of +22% as of September 2024.

Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Vertex Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations ...